Omeros Corp (OMER)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

201 ELLIOTT AVENUE WEST SEATTLE, WA 98119

Omeros is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. Its commercial product OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3% continues to gain market share in cataract surgery. Omeros' lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application under priority review by FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, atypical hemolytic uremic syndrome and COVID-19. OMS906, Omeros' inhibitor of MASP-3, the key activator of the alternative pathway of complement, is in a Phase 1 clinical trial, and the company's PDE7 inhibitor program OMS527, targeting addiction and movement disorders, has successfully completed a Phase 1 trial. Omeros' pipeline holds a diverse group of preclinical programs including a proprietary-asset-enabled antibody-generating technology and a proprietary GPCR platform through which it controls 54 GPCR drug targets and their corresponding compounds. One of these novel targets, GPR174, modulates a new cancer immunity axis recently discovered by Omeros, and the company is advancing GPR174-targeting antibodies and small-molecule inhibitors.

Data as of 2021-06-19 11:44:07 -0400
Market Cap938.665 Million Shares Outstanding62.328 Million Avg 30-day Volume550.131 Thousand
P/E Ratio-6.51308 Dividend Yield EPS-2.44
Price/Sales13.16 Debt to Equity-0.73 EBITDA-115.932 Million
Price to Book Value-4.23 Forward PE-7.68 Enterprise Value1.15 Billion
Total Cash100.483 Million Current Debt43.434 Million Gross Profit70.439 Million
BETA0.0 52-week High/Low23.85 / 9.25 Next Earnings Date2021-08-09 Price to Cash FLow (P/CF) -9999999.0
Data provided by IEX Cloud
View SEC Filings from OMER instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 1 1 0.0% 1 (0.06%) 1 (0.06%) 0.0%
Funds Holding: 151 138 9.42% 41 (2.41%) 36 (2.09%) 13.89%
13F shares: 34.517 Million 34.231 Million 0.84% 15.454 Million 16.087 Million -3.94%
% Ownership 55.7316 55.5222 0.38% 24.9517 26.0935 -4.38%
New Positions: 31 17 82.35% 13 7 85.71%
Increased Positions 37 43 -13.95% 6 7 -14.29%
Closed Positions 17 17 0.0% 8 9 -11.11%
Reduced Positions 55 42 30.95% 16 17 -5.88%
Total Calls 3.278 Million 2.41 Million 36.0% 1.71 Million 1.191 Million 43.61%
Total Puts 1.466 Million 841.55 Thousand 74.25% 645.2 Thousand 81.4 Thousand 692.63%
PUT/CALL Ratio 0.45 0.35 28.57% 0.38 0.07 442.86%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding OMER (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding OMER BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

147.4 Thousand total shares from 4 transactions

Exercise Derivative Conversion (M)

147.4 Thousand total shares from 4 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

DEMOPULOS GREGORY A MD CHAIRMAN, CEO & PRESIDENT

4,090,829 2021-06-15 3

DEMOPULOS PETER A MD

198,516 2021-02-22 1

JACOBSEN MICHAEL A VP FINANCE AND CAO

166,100 2021-02-19 3

HOOD LEROY E. MD PHD

74,390 2021-02-12 1

CABLE THOMAS J.

35,067 2021-01-13 1

CANCELMO PETER B VP, GEN. COUNSEL & CORP. SEC.

0 2020-10-26 1

ASPIRI RAY

0 2020-06-05 0

HANISH ARNOLD C

0 2020-06-05 0

SHAH RAJIV

0 2020-06-05 0

BUMOL THOMAS F.

0 2020-06-05 0

ZUMWALT KURT

  • Director
1,000 2020-02-10 0

KELBON MARCIA S. VP PATENT AND GENERAL COUNSEL

  • Officer
210,645 2019-06-07 0

SPIEGELMAN DANIEL K

  • Director
0 2012-06-01 0

TRIPET JEAN-PHILIPPE

  • Director
0 2011-05-27 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

DEMOPULOS GREGORY A MD CHAIRMAN, CEO & PRESIDENT

2021-06-17 20:30:16 -0400 2021-06-17 M 36,857 d 0 direct

DEMOPULOS GREGORY A MD CHAIRMAN, CEO & PRESIDENT

2021-06-17 20:30:16 -0400 2021-06-17 M 36,857 $4.10 a 2,063,843 direct 1.7264 1.7264 2 0.0 1

DEMOPULOS GREGORY A MD CHAIRMAN, CEO & PRESIDENT

2021-06-17 20:30:16 -0400 2021-06-17 S 36,857 $14.90 d 2,026,986 direct yes 1.7264 1.7264 2 0.0 1

DEMOPULOS GREGORY A MD CHAIRMAN, CEO & PRESIDENT

2021-06-17 20:30:16 -0400 2021-06-15 M 36,856 d 36,857 direct

DEMOPULOS GREGORY A MD CHAIRMAN, CEO & PRESIDENT

2021-06-17 20:30:16 -0400 2021-06-15 S 36,856 $15.02 d 2,026,986 direct yes 1.7264 1.7264 2 0.0 1

DEMOPULOS GREGORY A MD CHAIRMAN, CEO & PRESIDENT

2021-06-17 20:30:16 -0400 2021-06-15 M 36,856 $4.10 a 2,063,842 direct 1.7264 1.7264 2 0.0 1

DEMOPULOS GREGORY A MD CHAIRMAN, CEO & PRESIDENT

2021-05-21 18:45:16 -0400 2021-05-20 M 36,856 d 73,713 direct

DEMOPULOS GREGORY A MD CHAIRMAN, CEO & PRESIDENT

2021-05-21 18:45:16 -0400 2021-05-20 M 36,856 $4.10 a 2,063,842 direct -2.5016 1.0533 1.0533 6 -2.5016 2

DEMOPULOS GREGORY A MD CHAIRMAN, CEO & PRESIDENT

2021-05-21 18:45:16 -0400 2021-05-20 S 36,856 $14.96 d 2,026,986 direct yes -2.5016 1.0533 1.0533 6 -2.5016 2

DEMOPULOS GREGORY A MD CHAIRMAN, CEO & PRESIDENT

2021-05-21 18:45:16 -0400 2021-05-19 M 36,857 $4.10 a 2,063,843 direct -2.5016 1.0533 1.0533 6 -2.5016 2

DEMOPULOS GREGORY A MD CHAIRMAN, CEO & PRESIDENT

2021-05-21 18:45:16 -0400 2021-05-19 M 36,857 d 110,569 direct

DEMOPULOS GREGORY A MD CHAIRMAN, CEO & PRESIDENT

2021-05-21 18:45:16 -0400 2021-05-19 S 36,857 $17.07 d 2,026,986 direct yes -2.5016 1.0533 1.0533 6 -2.5016 2

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
OMEROS CORP OMER 2021-06-23 19:15:03 UTC -0.6171 0.6971 1700000
OMEROS CORP OMER 2021-06-23 18:45:02 UTC -0.6057 0.6857 1700000
OMEROS CORP OMER 2021-06-23 18:15:03 UTC -0.6057 0.6857 1700000
OMEROS CORP OMER 2021-06-23 17:45:02 UTC -0.6057 0.6857 1700000
OMEROS CORP OMER 2021-06-23 17:15:03 UTC -0.6057 0.6857 1700000
OMEROS CORP OMER 2021-06-23 16:45:03 UTC -0.6057 0.6857 1700000
OMEROS CORP OMER 2021-06-23 16:15:03 UTC -0.6057 0.6857 1700000
OMEROS CORP OMER 2021-06-23 15:45:03 UTC -0.597 0.677 1700000
OMEROS CORP OMER 2021-06-23 15:15:03 UTC -0.597 0.677 1700000
OMEROS CORP OMER 2021-06-23 14:45:03 UTC -0.5147 0.5947 1700000
OMEROS CORP OMER 2021-06-23 14:15:02 UTC -0.5147 0.5947 1700000
OMEROS CORP OMER 2021-06-23 13:45:03 UTC -0.5147 0.5947 1700000
OMEROS CORP OMER 2021-06-23 13:15:03 UTC -0.5147 0.5947 1700000
OMEROS CORP OMER 2021-06-23 12:45:03 UTC -0.5147 0.5947 1700000
OMEROS CORP OMER 2021-06-22 22:15:03 UTC -0.5147 0.5947 1700000
OMEROS CORP OMER 2021-06-22 21:45:03 UTC -0.5147 0.5947 1700000
OMEROS CORP OMER 2021-06-22 21:15:02 UTC -0.5147 0.5947 1700000
OMEROS CORP OMER 2021-06-22 20:45:03 UTC -0.5167 0.5967 1700000
OMEROS CORP OMER 2021-06-22 20:15:04 UTC -0.5167 0.5967 1700000
OMEROS CORP OMER 2021-06-22 19:45:03 UTC -0.5167 0.5967 1700000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
Franklin Alternative Strategies Funds- Franklin K2 Alternative Strategies Fund OMER -34697.0 shares, $-691858.18 2021-02-26 N-PORT
THE LAZARD FUNDS, INC.- Lazard Enhanced Opportunities Portfolio OMER -7958.0 shares, $-141652.4 2021-03-31 N-PORT
Advanced Series Trust- AST Academic Strategies Asset Allocation Portfolio OMER -7800.0 shares, $-138840.0 2021-03-31 N-PORT
AQR Funds- AQR Diversified Arbitrage Fund OMER -197208.0 shares, $-3510302.4 2021-03-31 N-PORT
JNL Series Trust- JNL Multi-Manager Alternative Fund OMER -56483.0 shares, $-1005397.4 2021-03-31 N-PORT

Elevate your investments